Quantcast

Latest Human Genome Sciences Stories

2009-02-19 07:00:00

ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the year ended December 31, 2008. These results are expected to be disclosed on Thursday, February 26, 2009, after the capital markets close. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The conference call will be hosted by senior management and will be held on Thursday, February 26, 2009...

2009-02-17 08:16:00

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (NYSE: GSK) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria(R) (albiglutide) in the long-term treatment of type 2 diabetes mellitus. As a result, HGS will receive a $9 million milestone payment in the first quarter of 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "We are delighted...

2009-02-02 05:00:00

- Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS - ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has begun delivery of 20,000 doses of its human monoclonal antibody drug ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the treatment of inhalation anthrax. (Photo: http://www.newscom.com/cgi-bin/prnh/20090202/PH65324 ) (Logo:...

2009-01-12 06:23:00

- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 financial guidance; expects less than $25 million net cash burn - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will announce its priority goals for 2009 and report on the Company's progress toward...

2009-01-12 06:00:00

- Trial conducted by Novartis to evaluate safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has initiated dosing in a Phase 2b trial that will evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with ribavirin in...

2009-01-09 15:00:00

ROCKVILLE, Md., Jan. 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 27th Annual JPMorgan Healthcare Conference will be webcast and may be accessed at www.hgsi.com (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) A member of Human Genome Sciences' senior management team will present an overview of the company on Wednesday, January 14, 2009 at 7:30 am Pacific Time (10:30 am Eastern Time). Investors interested...

2008-12-18 09:09:00

ROCKVILLE, Md., Dec. 18 /PRNewswire-FirstCall/ -- Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated the first pivotal trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with chronic coronary heart disease. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on...

2008-12-08 06:00:00

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, severe adverse events and discontinuations due to adverse events, vs. peginterferon alfa-2a - ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that...

2008-09-02 18:00:07

ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone. (Logo:...

2008-08-29 06:00:55

Human Genome Sciences has completed enrollment and initial dosing in Bliss-76, the second of two pivotal Phase III randomized clinical trials of LymphoStat-B in patients with active systemic lupus erythematosus. Belimumab is being developed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. The belimumab Phase III development program includes two double-blind, placebo-controlled, multi-center Phase...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related